NovaBridge Biosciences (FRA:0VY)
Germany · Delayed Price · Currency is EUR 1.630
+0.020 (1.24%)
At close: Aug 26, 2026
NovaBridge Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 0.63 | -1.55 | 13.86 | |
Revenue Growth | - | - | - | - | - | -94.14% |
Cost of Revenue | - | - | - | - | - | 7.31 |
Gross Profit | - | - | - | 0.63 | -1.55 | 6.55 |
Selling, General & Admin | 49.47 | 31.36 | 29.66 | 28.16 | 28.98 | 141.67 |
Research & Development | 73.16 | 62.91 | 21.77 | 21.45 | 22.55 | 190.94 |
Operating Expenses | 122.63 | 94.27 | 51.43 | 49.61 | 51.53 | 332.6 |
Operating Income | -122.63 | -94.27 | -51.43 | -48.98 | -53.08 | -326.06 |
Interest & Investment Income | 6.29 | 7.61 | 7.49 | 9.29 | 4.95 | 3.36 |
Earnings From Equity Investments | - | - | -1.04 | -11.4 | -64.71 | -57.91 |
Currency Exchange Gain (Loss) | 0.16 | -0 | -5.57 | -8.04 | -33.75 | 3.99 |
Other Non Operating Income (Expenses) | 0.06 | 0.07 | 14.49 | -0.05 | 5.48 | 4.32 |
EBT Excluding Unusual Items | -116.13 | -86.59 | -36.06 | -59.18 | -141.1 | -372.3 |
Impairment of Goodwill | - | - | - | -23.04 | - | - |
Gain (Loss) on Sale of Investments | -1.42 | -1.75 | - | - | - | 4.78 |
Asset Writedown | - | - | -1.25 | - | - | - |
Other Unusual Items | - | - | -12.39 | - | - | - |
Pretax Income | -117.55 | -88.34 | -49.7 | -82.22 | -141.1 | -367.52 |
Income Tax Expense | - | - | - | - | 0.1 | -0.5 |
Earnings From Continuing Operations | -117.55 | -88.34 | -49.7 | -82.22 | -141.2 | -367.02 |
Earnings From Discontinued Operations | - | - | 27.47 | -125.51 | -229.85 | - |
Net Income | -117.55 | -88.34 | -22.23 | -207.73 | -371.05 | -367.02 |
Net Income to Common | -117.55 | -88.34 | -22.23 | -207.73 | -371.05 | -367.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 113 | 96 | 81 | 83 | 83 | 76 |
Shares Outstanding (Diluted) | 113 | 96 | 81 | 83 | 83 | 76 |
Shares Change | 38.28% | 17.96% | -2.45% | 0.86% | 8.63% | 11.11% |
EPS (Basic) | -1.04 | -0.92 | -0.27 | -2.50 | -4.50 | -4.83 |
EPS (Diluted) | -1.04 | -0.92 | -0.27 | -2.50 | -4.50 | -4.83 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -46.67 | -20.6 | -106.68 | -146.66 | -92.32 | -157.89 |
Free Cash Flow Per Share | -0.41 | -0.21 | -1.31 | -1.76 | -1.12 | -2.08 |
Gross Margin | - | - | - | 100.00% | - | 47.25% |
Operating Margin | - | - | - | -7749.37% | - | -2353.06% |
Profit Margin | - | - | - | -32868.51% | - | -2648.70% |
Free Cash Flow Margin | - | - | - | -23206.33% | - | -1139.46% |
EBITDA | -122.53 | -94.2 | -51.17 | -48.5 | -52.87 | -323.89 |
D&A For EBITDA | 0.11 | 0.07 | 0.26 | 0.48 | 0.21 | 2.17 |
EBIT | -122.63 | -94.27 | -51.43 | -48.98 | -53.08 | -326.06 |
Revenue as Reported | - | - | - | 0.63 | -1.55 | 13.86 |